Page last updated: 2024-11-08

gant58

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

GANT58: inhibits hedgehog signalling; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID253078
CHEMBL ID472994
CHEBI ID94284
SCHEMBL ID15150098
MeSH IDM000600340

Synonyms (56)

Synonym
gant58
4,4',4'',4'''-(thiophene-2,3,4,5-tetrayl)tetrapyridine
HY-13282
NCI60_041654
4-(2,4,5-tri(4-pyridinyl)-3-thienyl)pyridine
mls000736819 ,
NSC75503 ,
pyridine,4',4'',4'''-(2,3,4,5-thiophenetetrayl)tetrakis-
nsc-75503
64048-12-0
NCGC00013822
pyridine, 4,4',4'',4'''- (2,3,4,5-thiophenetetrayl)tetrakis-
NCI75503
smr000447043
NCISTRUC2_001490
NCISTRUC1_001570
NCGC00096932-01
4,4'',4'''',4''''''-(thiophene-2,3,4,5-tetrayl)tetrapyridine
bdbm50249102
4-(3,4,5-tri(pyridin-4-yl)thiophen-2-yl)pyridine
CHEMBL472994 ,
4-(2,4,5-tripyridin-4-ylthiophen-3-yl)pyridine
gant 58
143222-43-9
CCG-36926
NCGC00013822-02
2,3,4,5-tetra(4-pyridyl)thiophene
HMS2807J23
gant58,nsc75503
FT-0616990
NCGC00013822-03
CS-0507
BRD-K64451768-001-01-3
c24h16n4s
AKOS024363180
SCHEMBL15150098
HB3313
DTXSID20291438
4,4',4'',4'''-(thiene-2,3,4,5-tetrayl)tetrapyridine
CHEBI:94284
gant58, >=98% (hplc)
Q27166094
4-(2,4,5-tripyridin-4-yl-3-thiophenyl)pyridine
hh/gli antagonist, gant58 - cas 64048-12-0
2,3,4,5-tetra-(4-pyridyl) thiophene
E76982
2,3,4,5-tetra-(4-pyridyl)-thiophene
gant-58
nsc 75503
nsc 75503nsc 75503
2,3,4,5-tetra-(4-pyridyl)thiophene
hh/gli antagonist, gant58
AS-78051
A914945
AC-36921
2,3,4,5-tetra(4-pyridyl)thiophene and nsc 75503

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
pyridinesAny organonitrogen heterocyclic compound based on a pyridine skeleton and its substituted derivatives.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (39)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency25.11890.003245.467312,589.2998AID2517
Chain A, JmjC domain-containing histone demethylation protein 3AHomo sapiens (human)Potency28.18380.631035.7641100.0000AID504339
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency25.11890.177814.390939.8107AID2147
ATAD5 protein, partialHomo sapiens (human)Potency18.34890.004110.890331.5287AID504467
TDP1 proteinHomo sapiens (human)Potency8.06370.000811.382244.6684AID686978; AID686979
Microtubule-associated protein tauHomo sapiens (human)Potency10.00000.180013.557439.8107AID1460
isocitrate dehydrogenase 1, partialHomo sapiens (human)Potency39.76796.309627.099079.4328AID602179; AID623995; AID624002
EWS/FLI fusion proteinHomo sapiens (human)Potency23.87560.001310.157742.8575AID1259252; AID1259253; AID1259255; AID1259256
bromodomain adjacent to zinc finger domain 2BHomo sapiens (human)Potency89.12510.707936.904389.1251AID504333
cytochrome P450 2D6 isoform 1Homo sapiens (human)Potency3.16230.00207.533739.8107AID891
cytochrome P450 2C19 precursorHomo sapiens (human)Potency1.58490.00255.840031.6228AID899
cytochrome P450 2C9 precursorHomo sapiens (human)Potency1.99530.00636.904339.8107AID883
nuclear factor erythroid 2-related factor 2 isoform 2Homo sapiens (human)Potency8.19950.00419.984825.9290AID504444
peptidyl-prolyl cis-trans isomerase NIMA-interacting 1Homo sapiens (human)Potency21.33130.425612.059128.1838AID504891
DNA polymerase eta isoform 1Homo sapiens (human)Potency19.95260.100028.9256213.3130AID588591
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency25.11890.050127.073689.1251AID588590
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency0.31620.031610.279239.8107AID884; AID885
muscleblind-like protein 1 isoform 1Homo sapiens (human)Potency31.62280.00419.962528.1838AID2675
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency0.31621.000012.224831.6228AID885
Glycoprotein hormones alpha chainHomo sapiens (human)Potency5.62344.46688.344810.0000AID624291
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency0.31621.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency0.31621.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency0.31621.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency0.31621.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency0.31621.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency0.31621.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency0.31621.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency0.31621.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency0.31621.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency0.31621.000012.224831.6228AID885
Histamine H2 receptorCavia porcellus (domestic guinea pig)Potency1.99530.00638.235039.8107AID883
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency0.31621.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency0.31621.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency0.31621.000012.224831.6228AID885
GABA theta subunitRattus norvegicus (Norway rat)Potency0.31621.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency0.31621.000012.224831.6228AID885
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Zinc finger protein GLI1Mus musculus (house mouse)IC50 (µMol)5.00005.00005.00005.0000AID1525383
Zinc finger protein GLI2Mus musculus (house mouse)IC50 (µMol)5.00005.00005.00005.0000AID1525383
Sonic hedgehog proteinMus musculus (house mouse)IC50 (µMol)5.00000.00301.19115.0000AID351760
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (14)

Processvia Protein(s)Taxonomy
G protein-coupled receptor signaling pathwayGlycoprotein hormones alpha chainHomo sapiens (human)
positive regulation of cell population proliferationGlycoprotein hormones alpha chainHomo sapiens (human)
hormone-mediated signaling pathwayGlycoprotein hormones alpha chainHomo sapiens (human)
regulation of signaling receptor activityGlycoprotein hormones alpha chainHomo sapiens (human)
positive regulation of steroid biosynthetic processGlycoprotein hormones alpha chainHomo sapiens (human)
positive regulation of cell migrationGlycoprotein hormones alpha chainHomo sapiens (human)
thyroid gland developmentGlycoprotein hormones alpha chainHomo sapiens (human)
luteinizing hormone secretionGlycoprotein hormones alpha chainHomo sapiens (human)
organ growthGlycoprotein hormones alpha chainHomo sapiens (human)
follicle-stimulating hormone signaling pathwayGlycoprotein hormones alpha chainHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIGlycoprotein hormones alpha chainHomo sapiens (human)
negative regulation of organ growthGlycoprotein hormones alpha chainHomo sapiens (human)
follicle-stimulating hormone secretionGlycoprotein hormones alpha chainHomo sapiens (human)
thyroid hormone generationGlycoprotein hormones alpha chainHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIZinc finger protein GLI2Mus musculus (house mouse)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (3)

Processvia Protein(s)Taxonomy
hormone activityGlycoprotein hormones alpha chainHomo sapiens (human)
protein bindingGlycoprotein hormones alpha chainHomo sapiens (human)
follicle-stimulating hormone activityGlycoprotein hormones alpha chainHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (9)

Processvia Protein(s)Taxonomy
extracellular regionGlycoprotein hormones alpha chainHomo sapiens (human)
extracellular spaceGlycoprotein hormones alpha chainHomo sapiens (human)
Golgi lumenGlycoprotein hormones alpha chainHomo sapiens (human)
follicle-stimulating hormone complexGlycoprotein hormones alpha chainHomo sapiens (human)
pituitary gonadotropin complexGlycoprotein hormones alpha chainHomo sapiens (human)
extracellular spaceGlycoprotein hormones alpha chainHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
nucleoplasmZinc finger protein GLI2Mus musculus (house mouse)
cytosolZinc finger protein GLI2Mus musculus (house mouse)
extracellular regionSonic hedgehog proteinMus musculus (house mouse)
nucleoplasmSonic hedgehog proteinMus musculus (house mouse)
endoplasmic reticulum lumenSonic hedgehog proteinMus musculus (house mouse)
plasma membraneSonic hedgehog proteinMus musculus (house mouse)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (73)

Assay IDTitleYearJournalArticle
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1224817Assays to identify small molecules inhibitory for eIF4E expression2015Chemistry & biology, Jul-23, Volume: 22, Issue:7
Internal Ribosome Entry Site-Based Bicistronic In Situ Reporter Assays for Discovery of Transcription-Targeted Lead Compounds.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID358328Reduction in GLI1 expression in human PANC1 cells at 5 uM2007Proceedings of the National Academy of Sciences of the United States of America, May-15, Volume: 104, Issue:20
Inhibition of GLI-mediated transcription and tumor cell growth by small-molecule antagonists.
AID358315Reduction of GLI1 mediated transcription in HEK293 cells by luciferase reporter assay2007Proceedings of the National Academy of Sciences of the United States of America, May-15, Volume: 104, Issue:20
Inhibition of GLI-mediated transcription and tumor cell growth by small-molecule antagonists.
AID358321Inhibition of Hedgehog signaling in human Shh-L2 cells2007Proceedings of the National Academy of Sciences of the United States of America, May-15, Volume: 104, Issue:20
Inhibition of GLI-mediated transcription and tumor cell growth by small-molecule antagonists.
AID358349Effect on Hedgehog signaling in mouse NIH3T3 cells assessed as activation of TNF signaling2007Proceedings of the National Academy of Sciences of the United States of America, May-15, Volume: 104, Issue:20
Inhibition of GLI-mediated transcription and tumor cell growth by small-molecule antagonists.
AID1196822Inhibition of GLI (unknown origin) expressed in HEK293 cells assessed as reduction in GLI-mediated transcription at 30 uM2015Journal of medicinal chemistry, Feb-12, Volume: 58, Issue:3
Discovery of small molecule inhibitors to Krüppel-like factor 10 (KLF10): implications for modulation of T regulatory cell differentiation.
AID358348Inhibition of nuclear accumulation of wild type GLI in HEK293 cells2007Proceedings of the National Academy of Sciences of the United States of America, May-15, Volume: 104, Issue:20
Inhibition of GLI-mediated transcription and tumor cell growth by small-molecule antagonists.
AID358350Effect on Hedgehog signaling in mouse NIH3T3 cells assessed as activation of NF kappaB2007Proceedings of the National Academy of Sciences of the United States of America, May-15, Volume: 104, Issue:20
Inhibition of GLI-mediated transcription and tumor cell growth by small-molecule antagonists.
AID358339Induction of apoptosis in human Jurkat cells assessed as caspase3/7 cleavage by luminometric assay2007Proceedings of the National Academy of Sciences of the United States of America, May-15, Volume: 104, Issue:20
Inhibition of GLI-mediated transcription and tumor cell growth by small-molecule antagonists.
AID358341Induction of apoptosis in human DU146 cells assessed as caspase3/7 cleavage by luminometric assay2007Proceedings of the National Academy of Sciences of the United States of America, May-15, Volume: 104, Issue:20
Inhibition of GLI-mediated transcription and tumor cell growth by small-molecule antagonists.
AID509548Antagonist activity at hedgehog receptor2010Bioorganic & medicinal chemistry, Sep-15, Volume: 18, Issue:18
Modulators of the hedgehog signaling pathway.
AID358346Alteration in DNA binding to GLI1 in HEK293 cells2007Proceedings of the National Academy of Sciences of the United States of America, May-15, Volume: 104, Issue:20
Inhibition of GLI-mediated transcription and tumor cell growth by small-molecule antagonists.
AID358333Inhibition of Gli1 dependent growth of human Jurkat cells at 5 uM2007Proceedings of the National Academy of Sciences of the United States of America, May-15, Volume: 104, Issue:20
Inhibition of GLI-mediated transcription and tumor cell growth by small-molecule antagonists.
AID358343Reduction of expression of PTCH mRNA in human 22Rv cells2007Proceedings of the National Academy of Sciences of the United States of America, May-15, Volume: 104, Issue:20
Inhibition of GLI-mediated transcription and tumor cell growth by small-molecule antagonists.
AID358340Induction of apoptosis in HEK293 cells assessed as caspase3/7 cleavage by luminometric assay2007Proceedings of the National Academy of Sciences of the United States of America, May-15, Volume: 104, Issue:20
Inhibition of GLI-mediated transcription and tumor cell growth by small-molecule antagonists.
AID358323Reduction of Ptch1-lacZ level in mouse embryonic fibroblast by luminometric assay2007Proceedings of the National Academy of Sciences of the United States of America, May-15, Volume: 104, Issue:20
Inhibition of GLI-mediated transcription and tumor cell growth by small-molecule antagonists.
AID358342Induction of apoptosis in mouse NIH3T3 cells assessed as caspase3/7 cleavage by luminometric assay2007Proceedings of the National Academy of Sciences of the United States of America, May-15, Volume: 104, Issue:20
Inhibition of GLI-mediated transcription and tumor cell growth by small-molecule antagonists.
AID358327Inhibition of Hedgehog/Gli1 mediated transformation in mouse NIH3T3 cells at 10 uM2007Proceedings of the National Academy of Sciences of the United States of America, May-15, Volume: 104, Issue:20
Inhibition of GLI-mediated transcription and tumor cell growth by small-molecule antagonists.
AID358352Effect on Hedgehog signaling in mouse NIH3T3 cells assessed as transactivation of Ras-Raf-Mek-Mapk cascade2007Proceedings of the National Academy of Sciences of the United States of America, May-15, Volume: 104, Issue:20
Inhibition of GLI-mediated transcription and tumor cell growth by small-molecule antagonists.
AID358334Inhibition of Gli1 dependent growth of human PANC1 cells at 5 uM2007Proceedings of the National Academy of Sciences of the United States of America, May-15, Volume: 104, Issue:20
Inhibition of GLI-mediated transcription and tumor cell growth by small-molecule antagonists.
AID358326Reduction in expression of Hedgehog target gene Hip1 in Sufu deficient mouse MEF cells2007Proceedings of the National Academy of Sciences of the United States of America, May-15, Volume: 104, Issue:20
Inhibition of GLI-mediated transcription and tumor cell growth by small-molecule antagonists.
AID358332Inhibition of Gli1 dependent growth of human HepG2 cells at 5 uM2007Proceedings of the National Academy of Sciences of the United States of America, May-15, Volume: 104, Issue:20
Inhibition of GLI-mediated transcription and tumor cell growth by small-molecule antagonists.
AID358329Reduction in PTCH expression in human PANC1 cells at 5 uM2007Proceedings of the National Academy of Sciences of the United States of America, May-15, Volume: 104, Issue:20
Inhibition of GLI-mediated transcription and tumor cell growth by small-molecule antagonists.
AID1525383Inhibition of GLI1/GLI2 in mouse Shh Light2 cells assessed as reduction in endogenous hedgehog signalling in presence of Smo agonist SAG by luciferase reporter gene assay2019Journal of medicinal chemistry, 09-26, Volume: 62, Issue:18
Inhibiting Hedgehog: An Update on Pharmacological Compounds and Targeting Strategies.
AID358324Inhibition of beta galactosidase in HEK293 cells2007Proceedings of the National Academy of Sciences of the United States of America, May-15, Volume: 104, Issue:20
Inhibition of GLI-mediated transcription and tumor cell growth by small-molecule antagonists.
AID358330Reduction in GlI1 expression in human 22Rv cells at 5 uM2007Proceedings of the National Academy of Sciences of the United States of America, May-15, Volume: 104, Issue:20
Inhibition of GLI-mediated transcription and tumor cell growth by small-molecule antagonists.
AID358345Inhibition of GLI via PKA activation in HEK293 cells2007Proceedings of the National Academy of Sciences of the United States of America, May-15, Volume: 104, Issue:20
Inhibition of GLI-mediated transcription and tumor cell growth by small-molecule antagonists.
AID358351Effect on Hedgehog signaling in mouse NIH3T3 cells assessed as transactivation of glucocorticoid receptor2007Proceedings of the National Academy of Sciences of the United States of America, May-15, Volume: 104, Issue:20
Inhibition of GLI-mediated transcription and tumor cell growth by small-molecule antagonists.
AID358317Inhibition of GLI1 induced hedgehog signaling in mouse NIH3T3 cells2007Proceedings of the National Academy of Sciences of the United States of America, May-15, Volume: 104, Issue:20
Inhibition of GLI-mediated transcription and tumor cell growth by small-molecule antagonists.
AID358322Reduction of Gil1 mRNA levels at 10 uM in Ptch deficient mouse embryonic fibroblast2007Proceedings of the National Academy of Sciences of the United States of America, May-15, Volume: 104, Issue:20
Inhibition of GLI-mediated transcription and tumor cell growth by small-molecule antagonists.
AID358353Antiproliferative activity against Ptch deficient mouse embryonic fibroblast at 10 uM by BrdU incorporation2007Proceedings of the National Academy of Sciences of the United States of America, May-15, Volume: 104, Issue:20
Inhibition of GLI-mediated transcription and tumor cell growth by small-molecule antagonists.
AID358335Inhibition of Gli1 dependent growth of human 22Rv cells at 5 uM2007Proceedings of the National Academy of Sciences of the United States of America, May-15, Volume: 104, Issue:20
Inhibition of GLI-mediated transcription and tumor cell growth by small-molecule antagonists.
AID358347Inhibition of nuclear accumulation of GLI mutant in HEK293 cells2007Proceedings of the National Academy of Sciences of the United States of America, May-15, Volume: 104, Issue:20
Inhibition of GLI-mediated transcription and tumor cell growth by small-molecule antagonists.
AID358338Induction of apoptosis in human 22Rv1 cells assessed as caspase3/7 cleavage by luminometric assay2007Proceedings of the National Academy of Sciences of the United States of America, May-15, Volume: 104, Issue:20
Inhibition of GLI-mediated transcription and tumor cell growth by small-molecule antagonists.
AID358325Reduction in expression of Hedgehog target gene Gli1 in Sufu deficient mouse embryonic fibroblast2007Proceedings of the National Academy of Sciences of the United States of America, May-15, Volume: 104, Issue:20
Inhibition of GLI-mediated transcription and tumor cell growth by small-molecule antagonists.
AID358337Induction of apoptosis in human HepG2 cells assessed as caspase3/7 cleavage by luminometric assay2007Proceedings of the National Academy of Sciences of the United States of America, May-15, Volume: 104, Issue:20
Inhibition of GLI-mediated transcription and tumor cell growth by small-molecule antagonists.
AID358331Reduction in PTCH expression in human 22Rv cells at 5 uM2007Proceedings of the National Academy of Sciences of the United States of America, May-15, Volume: 104, Issue:20
Inhibition of GLI-mediated transcription and tumor cell growth by small-molecule antagonists.
AID351760Inhibition of SHH in mouse Shh Light2 cells by GLI-responsive firefly luciferase reporter gene assay2009Journal of medicinal chemistry, Jul-09, Volume: 52, Issue:13
Hedgehog-Gli signaling pathway inhibitors as anticancer agents.
AID358336Antitumor activity in GLI1 positive human 22Rv cells xenografted mouse model at 50 mg/kg, sc after 18 days2007Proceedings of the National Academy of Sciences of the United States of America, May-15, Volume: 104, Issue:20
Inhibition of GLI-mediated transcription and tumor cell growth by small-molecule antagonists.
AID358316Reduction of GLI2 mediated transcription in HEK293 cells by luciferase reporter assay2007Proceedings of the National Academy of Sciences of the United States of America, May-15, Volume: 104, Issue:20
Inhibition of GLI-mediated transcription and tumor cell growth by small-molecule antagonists.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (26)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (7.69)29.6817
2010's14 (53.85)24.3611
2020's10 (38.46)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 24.11

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index24.11 (24.57)
Research Supply Index3.30 (2.92)
Research Growth Index5.04 (4.65)
Search Engine Demand Index17.79 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (24.11)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews4 (15.38%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other22 (84.62%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]